Exploring Evolus, Inc. (EOLS) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Evolus, Inc. (EOLS) and what's driving their interest? As of the end of 2024, institutional investors held a significant stake, owning approximately 90.79% of the company's shares, with a total value of $632,771,000 USD. Are these investments a sign of confidence in Evolus's growth potential, especially with analysts projecting a 134.01% upside potential from the last price of $10.38, with an average price target of $24.29? Considering Evolus's aim for profitability by 2025 and a targeted $700 million in revenue by 2028, let's delve into the profiles of the major players and the factors influencing their investment decisions.

Evolus, Inc. (EOLS) Who Invests in Evolus, Inc. and Why?

Evolus, Inc. (EOLS) operates as a publicly traded company, with its shares available on stock exchanges, leading to a distributed ownership among institutional investors, retail shareholders, and company insiders.

As of December 31, 2024, Evolus, Inc. reported record full-year revenue of $202.0 million, a 36% increase year-over-year. The company's focus on the aesthetics sector, primarily through its neurotoxin Jeuveau (also marketed as Nuceiva internationally), has enabled it to capture market share actively. For the full year 2024, Evolus is projecting net revenue between $255 million and $265 million.

Here's a detailed look at the investor profile of Evolus, Inc. (EOLS):

Key Investor Types

The ownership of Evolus, Inc. is distributed among various types of investors:

• Institutional Investors: These include mutual funds, pension funds, hedge funds, and other large investment firms. As of recent filings, institutional investors hold a significant percentage of Evolus, Inc.'s shares. Institutional ownership is at 82.04%.
• Retail Investors: These are individual investors who buy shares of Evolus, Inc. through brokerage accounts.
• Company Insiders: This category includes the company's directors, executive officers, and other employees who hold shares of Evolus, Inc.. Individual insiders own 2.17% of the shares, which equates to 1,378,814 shares.
• Private Companies: Private companies hold 2,136,449 shares in Evolus, Inc.

Investment Motivations

Different investors are attracted to Evolus, Inc. for various reasons:

• Growth Prospects: Evolus, Inc. operates in the expanding aesthetics market, particularly with its flagship product Jeuveau. The company's revenue growth and market share gains attract investors seeking high-growth potential. Evolus aims for $700 million in revenue by 2028.
• Market Position: As a key player in the aesthetic neurotoxin market, with Jeuveau competing against established brands, Evolus, Inc. attracts investors who believe in its ability to disrupt and gain market share.
• Product Pipeline: The development and launch of new products, such as the Evolysse dermal filler line, provide additional growth opportunities and attract investors interested in the company's long-term potential.
• Strategic Initiatives: Evolus's customer-centric approach, innovative digital platform, and strategic collaborations enhance its market position and appeal to investors.

Investment Strategies

Investors in Evolus, Inc. employ various strategies:

• Long-Term Holding: Some institutional investors, such as mutual funds and pension funds, may adopt a long-term holding strategy, based on the company's growth prospects and market position.
• Short-Term Trading: Hedge funds and other active investors may engage in short-term trading strategies to capitalize on stock price fluctuations and market trends.
• Value Investing: Some investors may view Evolus, Inc. as undervalued based on its growth potential and financial metrics, leading them to invest with a value investing approach.

Major Shareholders

Evolus, Inc.'s largest shareholders include:

• Perceptive Advisors Llc: 5,145,846 shares as of December 31, 2024.
• Tang Capital Management Llc: 4,997,399 shares as of December 31, 2024.
• Blackrock, Inc.: 4,364,896 shares as of December 31, 2024.
• Vanguard Group Inc.: 3,171,404 shares as of December 31, 2024.
• Nantahala Capital Management, Llc: 3,130,149 shares as of December 31, 2024.
• Caligan Partners Lp: 2,692,388 shares as of December 31, 2024.

These institutions hold significant stakes in Evolus, Inc., reflecting their confidence in the company's prospects.

The institutional ownership in Evolus, Inc. is substantial. As of April 15, 2025, 313 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 57,734,137 shares. This represents approximately 90.79% (excluding 13D/G) of the company's shares outstanding.

Here is a table summarizing the key institutional holders and their positions as of December 31, 2024:

These figures are based on the latest institutional holdings data for Evolus, Inc.

For further insights into Evolus, Inc.'s financial health, you can explore Breaking Down Evolus, Inc. (EOLS) Financial Health: Key Insights for Investors.

Evolus, Inc. (EOLS) Institutional Ownership and Major Shareholders of Evolus, Inc. (EOLS)

Institutional ownership in Evolus, Inc. (EOLS) reflects the confidence and investment strategies of large financial entities. These institutions often manage substantial funds and their investment decisions can significantly influence a company's stock price and overall market perception. Understanding the landscape of these major shareholders provides valuable insights into the stability and potential growth of Evolus, Inc. (EOLS). You can also learn about the company's history, mission, ownership, and business model at: Evolus, Inc. (EOLS): History, Ownership, Mission, How It Works & Makes Money

Here’s a look at some of the top institutional investors and their recent activity regarding Evolus, Inc. (EOLS).

Top Institutional Investors:

As of Q4 2023, the top institutional holders of Evolus, Inc. (EOLS) common stock included:

• AWM Investment Company Inc. held 2,739,975 shares, representing approximately 5.14% of the company.
• BlackRock Fund Advisors held 2,697,848 shares.
• Vanguard Group Inc held 2,493,367 shares.
• RA Capital Management, L.P. held 2,427,994 shares.
• State Street Corporation held 1,245,379 shares.

These major institutional investors play a crucial role in shaping the financial trajectory of Evolus, Inc. (EOLS) through their substantial holdings and strategic investment decisions.

Changes in Ownership:

Tracking changes in institutional ownership provides insights into the evolving sentiment of major investors. In Q4 2023, some notable changes were observed:

AWM Investment Company Inc. increased its stake by 41%, acquiring an additional 800,000 shares in Q4 2023. This suggests a bullish outlook on Evolus, Inc. (EOLS).

Conversely, other institutions may have reduced their positions, reflecting portfolio adjustments or a change in their investment thesis. Monitoring these shifts is essential to understanding the dynamics of investor confidence in Evolus, Inc. (EOLS).

Impact of Institutional Investors:

Institutional investors wield considerable influence over Evolus, Inc. (EOLS)'s stock price and strategic direction. Their actions can trigger significant market movements and influence smaller investors. Active engagement from these large stakeholders can also drive corporate governance improvements and strategic realignments.

The presence of prominent institutional holders often enhances a company's credibility and attractiveness to other investors. Their involvement can lead to greater stability in the stock's performance and provide a foundation for long-term growth.

Here is a summary table of Evolus, Inc. (EOLS) ownership data:

Evolus, Inc. (EOLS) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Evolus, Inc. (EOLS) provides valuable insights into the company's stability, growth potential, and strategic direction. Institutional investors, mutual funds, and individual shareholders collectively shape the market dynamics and influence corporate decisions. Examining the major holders and their recent activities offers a comprehensive view of investor sentiment and its potential impact on Evolus.

As of late 2024, 83.19% of Evolus' shares were held by institutions, demonstrating significant confidence from large financial entities. A total of 223 institutions held shares in the company. Institutional ownership indicates a certain degree of credibility and stability, though it's important to remember that even institutional investors can make incorrect assessments. The concentration of ownership among a few key players can also make the stock price sensitive to their trading decisions.

Here are the top institutional holders of Evolus, Inc. (EOLS) as of December 31, 2024:

• Perceptive Advisors Llc: Held 5.15 million shares, representing 8.09% of the outstanding shares, valued at $55,523,678.
• Tang Capital Management, LLC: Held 5 million shares, accounting for 7.86% of the company, with a value of $53,921,935.
• Blackrock Inc.: Held 4.36 million shares, or 6.86%, worth $47,097,227.
• Vanguard Group Inc: Held 3.17 million shares, comprising 4.99%, valued at $34,219,449.
• Nantahala Capital Management, LLC: Held 3.13 million shares, making up 4.92%, with a value of $33,774,307.
• Caligan Partners, LP: Held 2.69 million shares, which is 4.23%, valued at $29,050,866.
• State Street Corporation: Held 1.42 million shares, representing 2.24%, worth $15,347,361.
• Millennium Management Llc: Held 1.37 million shares, or 2.15%, valued at $14,765,284.
• Boothbay Fund Management, LLC: Held 1.29 million shares, accounting for 2.03%, with a value of $13,895,005.
• Stonepine Capital Management, LLC: Held 1.26 million shares, comprising 1.99% and valued at $13,645,584.

Top mutual fund holders include:

• VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund: Holding 1.69 million shares, representing 2.65%, valued at $18,199,406.
• iShares Trust-iShares Russell 2000 ETF: Holding 1.47 million shares as of March 31, 2025, accounting for 2.31%, with a value of $15,838,123.

Institutional investors often measure their performance against benchmarks, increasing their interest in a stock once it is included in a major index. Evolus has a notable institutional presence, which suggests a degree of credibility within the investment community.

Recent changes in holdings reflect the dynamic nature of investor sentiment. For instance, between periods, some institutions increased their positions, while others reduced theirs:

Evolus's institutional ownership structure reveals the current positions held by institutions and funds, along with recent changes in their holdings. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Forms filed with the Securities Exchange Commission (SEC), such as Schedule 13D, indicate investors holding more than 5% of the company with the intent to actively pursue changes in business strategy, while Schedule 13G indicates a passive investment exceeding 5%.

Institutional investors holding a significant percentage of Evolus's shares can exert considerable influence on the company's decisions and stock performance. Their actions, driven by in-depth research and analysis, can signal confidence or concern about the company's prospects. Monitoring these investors' moves is crucial for understanding market sentiment and potential shifts in Evolus's valuation.

For more insights into Evolus, Inc.'s mission, vision, and core values, explore: Mission Statement, Vision, & Core Values of Evolus, Inc. (EOLS).

Evolus, Inc. (EOLS) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Evolus, Inc. (EOLS) is crucial for assessing the company's current standing and future prospects. Analyzing major shareholders' attitudes, recent market behaviors, and analyst perspectives provides a comprehensive view of the factors influencing Evolus's stock performance.

Investor sentiment toward Evolus, Inc. (EOLS) can be gauged by examining the positions of major shareholders. While specific sentiments (positive, neutral, or negative) aren't always explicitly stated, changes in holdings and trading activity can offer insights. Institutional investors' decisions to increase, decrease, or maintain their stakes often reflect their outlook on the company's potential. Monitoring these movements provides a sense of overall confidence or concern among significant investors.

Recent market reactions to Evolus, Inc. (EOLS) often correlate with significant changes in ownership or substantial investor moves. For example, a large institutional investor increasing its stake might lead to a positive market reaction, signaling confidence in the company's prospects. Conversely, a major sell-off could trigger a negative response, reflecting concerns about Evolus's performance or future outlook. Analyzing these market reactions helps in understanding how the investment community interprets and responds to key investor activities.

Analyst perspectives play a vital role in shaping the narrative around Evolus, Inc. (EOLS). Analysts offer insights on how key investors impact the company's future, considering factors like strategic alignment, financial stability, and growth potential. Their reports often delve into the rationale behind major investment decisions, providing context and forecasts that influence market sentiment. These analyses can highlight both opportunities and risks associated with Evolus, offering a balanced view for potential investors.

Key indicators to monitor include:

• Changes in institutional ownership percentages.
• Significant trading volumes following major investor announcements.
• Analyst ratings and price targets revisions.
• Market commentary and news articles discussing investor sentiment.

Here's a look at some potential data points regarding Evolus, Inc. (EOLS) investor profiles, though real-time data would need to be sourced from financial data providers:

Keeping track of these elements offers a well-rounded understanding of Evolus, Inc. (EOLS) investor dynamics and their influence on the company's market performance. For more insights into the company's direction, check out: Mission Statement, Vision, & Core Values of Evolus, Inc. (EOLS).